Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151 [Yahoo! Finance]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
granted a key U.S. patent covering a structurally novel DPP1 (Cathepsin C) inhibitor, currently developed as MLD-151 by Melodia Therapeutics and discovered by its partner, Alivexis, Inc., strengthening the intellectual property foundation supporting Melodia's lead development program. Melodia Therapeutics AG logo (PRNewsfoto/Melodia Therapeutics AG) The newly issued patent (U.S. Patent No. 12,522,593; International Application No. PCT/JP2023/021735), entitled "Azacycloalkyl Carbonyl Cyclic Amine Compound," is held by Alivexis, Inc. and Astellas Pharma Inc. and covers a proprietary compound series that Melodia licensed in June 2024 exclusively and on a global basis to develop, manufacture, and commercialize the program. MLD-151 is based on a structurally distinct chemotype that is clearly differentiated from earlier DPP1 inhibitors built on dipeptidyl nitrile scaffolds. MLD-151 and this novel chemotype was designed to enable differentiated pharmacology, including the potential fo
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge? [Yahoo! Finance]Yahoo! Finance
- Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
- Insmed Incorporated (INSM) Enters 2026 With Momentum [Yahoo! Finance]Yahoo! Finance
- Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In [Yahoo! Finance]Yahoo! Finance
- Insmed (NASDAQ:INSM) had its price target lowered by analysts at Mizuho from $211.00 to $204.00. They now have an "outperform" rating on the stock.MarketBeat
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 2/27/26 - Form 4
- 2/25/26 - Form 4
- 2/25/26 - Form 4
- INSM's page on the SEC website